Regencell Bioscience Holdings Ltd(RGC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 18 at 7:30 PM ET (Korea 9/19 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.01 | Insider Own | 88.68% | Shs Outstand | 494.5M | Perf Week | 2.66% |
| Market Cap | 2.87B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 56.1M | Perf Month | -0.34% |
| Enterprise Value | 2.87B | PEG | - | EPS next Q | - | Inst Own | 0.28% | Short Float | 1.7% | Perf Quarter | -51.79% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 63.21% | Short Ratio | 2.92 | Perf Half Y | -78.56% |
| Sales | 0.00B | P/B | 2344.13 | EPS next 5Y | - | ROA | -134.35% | Short Interest | 0.95M | Perf YTD | -72.43% |
| Book/sh | 0 | P/C | 1215.59 | EPS past 3/5Y | 22.39% -33.47% | ROE | -177.66% | 52W High | -91.61% ($69.00) | Perf Year | -61.78% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | -523.06% | 52W Low | 28.38% ($4.51) | Perf 3Y | 1635.17% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -71.08% | Gross Margin | - | Volatility(W/M) | 5.06% 8.89% | Perf 5Y | 998.45% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.53 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.42 | EPS Q/Q | -189.19% | Profit Margin | - | RSI (14) | 47.43 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.42 | Sales Q/Q | - | SMA20 | -0.22% ($5.8) | Beta | 1.18 | Target Price | - |
| Payout | - | Debt/Eq | 0.32 | Earnings | - | SMA50 | 2.43% ($5.65) | Rel Volume | 0.29 | Prev Close | $5.96 |
| Employees | 10 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | - | SMA200 | -70.51% ($19.63) | Avg Volume(3M) | 0.33M | Price | $5.79 |
| IPO | 2021/7/16 | Option/Short | Yes/Yes | Trades | 769 | Volume | 93,993 | Change | -2.85% |
Company
RGC is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A Hong Kong-based biotech company that is in the early stages of researching treatment candidates for neurodevelopmental disorders such as ADHD (Attention Deficit Hyperactivity Disorder), built on a foundation of traditional herbal medicine.
Over the past 1 year, on the lower side
92% below its 1-year high.
RGC has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Holding long would have paid off
Would have changed by +1635.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 0.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EEMO 0.00%
ONEQ 0.00%
GXC 0.00%
BKIE 0.00%
GSID 0.00%It ranks #4 in the industry
Based on market cap of $3B.
RGC $3B PER -
TAK $60B PER -
TEVA $45B PER 65.0
HLN $41B PER 19.1
FAQ
What kind of company is RGC?
RGC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of RGC?
The market cap of RGC is approximately $2.9B, ranking 1,812 within its sector.
What is the 52-week high and low for RGC?
RGC has recorded a 52-week high of $69.00 and a low of $4.51.
